Emergent BioSolutions (EBS) News Today $9.90 -0.07 (-0.65%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)January 16 at 8:00 AM | globenewswire.comEmergent BioSolutions Inc. to Present at J.P. Morgan Healthcare Conference, Releases Corporate Slide DeckJanuary 16 at 4:03 AM | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Upgraded to Buy at StockNews.comJanuary 16 at 2:37 AM | americanbankingnews.comRep. Steve Cohen Sells Off Shares of Emergent BioSolutions Inc. (NYSE:EBS)Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Emergent BioSolutions stock on December 11th. The trade occurred in the RepresJanuary 15 at 3:04 AM | marketbeat.comStockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to BuyStockNews.com upgraded Emergent BioSolutions from a "hold" rating to a "buy" rating in a research note on Tuesday.January 14, 2025 | marketbeat.comEmergent BioSolutions: Stock Is A Likely Winner In 2025January 14, 2025 | seekingalpha.comEmergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma PharmaceuticalsJanuary 14, 2025 | globenewswire.comEmergent BioSolutions receives contract option valued at $16.7MJanuary 14, 2025 | markets.businessinsider.comEmergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for EbolaJanuary 13, 2025 | globenewswire.comEmergent BioSolutions' (EBS) Buy Rating Reiterated at HC WainwrightJanuary 13, 2025 | americanbankingnews.comEmergent BioSolutions: Strong Buy Rating Driven by Government Contracts and Growth in Medical CountermeasuresJanuary 11, 2025 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS)HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Emergent BioSolutions in a research note on Friday.January 10, 2025 | marketbeat.comThose who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365%January 9, 2025 | finance.yahoo.comEmergent BioSolutions exercises $20M option to supply DoD with BioThraxJanuary 8, 2025 | markets.businessinsider.comEmergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025January 8, 2025 | globenewswire.comEmergent BioSolutions Inc. Secures $20 Million Contract Modification to Supply BioThrax® Vaccine to U.S. Department of DefenseJanuary 8, 2025 | quiverquant.comEmergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)January 8, 2025 | globenewswire.comEmergent BioSolutions rises 5.3%January 1, 2025 | markets.businessinsider.comEmergent BioSolutions initiated with a Buy at H.C. WainwrightDecember 30, 2024 | markets.businessinsider.comEmergent BioSolutions up 10% on HC Wainwright buy initiationDecember 30, 2024 | msn.comWhy Emergent BioSolutions Stock Blasted Higher TodayDecember 30, 2024 | fool.comEmergent BioSolutions (NYSE:EBS) Trading Up 11.9% - Should You Buy?Emergent BioSolutions (NYSE:EBS) Trading 11.9% Higher - Here's WhyDecember 30, 2024 | marketbeat.comEmergent BioSolutions (NYSE:EBS) Coverage Initiated at HC WainwrightHC Wainwright started coverage on shares of Emergent BioSolutions in a research report on Monday. They issued a "buy" rating and a $15.00 price target on the stock.December 30, 2024 | marketbeat.comStockNews.com Downgrades Emergent BioSolutions (NYSE:EBS) to HoldStockNews.com lowered shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Saturday.December 28, 2024 | marketbeat.comState Street Corp Purchases 1,713,200 Shares of Emergent BioSolutions Inc. (NYSE:EBS)State Street Corp increased its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 864.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,911,327 shares of the biopharmaceutical company's stock after purchaDecember 25, 2024 | marketbeat.comEmergent BioSolutions (NYSE:EBS) Lowered to "Hold" Rating by StockNews.comStockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Friday.December 20, 2024 | marketbeat.comEmergent BioSolutions receives $50M contract option from BARDADecember 17, 2024 | markets.businessinsider.comBNP Paribas Financial Markets Has $263,000 Holdings in Emergent BioSolutions Inc. (NYSE:EBS)BNP Paribas Financial Markets reduced its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 65.0% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 31,470 shares of the biopharmaceutical company's stock after selling 58December 17, 2024 | marketbeat.comEmergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)December 16, 2024 | markets.businessinsider.comDrugmaker seeks accelerated breakthrough for brain cancer treatmentDecember 13, 2024 | bizjournals.comOak Hill Advisors LP Acquires New Position in Emergent BioSolutions Inc. (NYSE:EBS)Oak Hill Advisors LP acquired a new stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,113,338 shares of the biopharmaceutical company's stock,December 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)Jacobs Levy Equity Management Inc. bought a new stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 185,317 shares of the biopharmaceutical compDecember 9, 2024 | marketbeat.comEmergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Point72 Asia Singapore Pte. Ltd.Point72 Asia Singapore Pte. Ltd. lessened its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 88.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,401 shares of the biopharDecember 7, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Cuts Stake in Emergent BioSolutions Inc. (NYSE:EBS)Charles Schwab Investment Management Inc. cut its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 29.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,224,727 sharesDecember 7, 2024 | marketbeat.comWhy Emergent BioSciences Stock Plummeted TodayDecember 3, 2024 | fool.comWHO determines mpox upsurge still constitutes public health emergencyNovember 23, 2024 | markets.businessinsider.comGeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail ThinksNovember 22, 2024 | msn.comEmergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M SettlementNovember 22, 2024 | benzinga.comEmergent BioSolutions (NYSE:EBS) Downgraded to Hold Rating by StockNews.comStockNews.com downgraded Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday.November 20, 2024 | marketbeat.comEmergent BioSolutions files to sell 3.61M shares of common stock for holdersNovember 14, 2024 | markets.businessinsider.comEmergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comEmergent BioSolutions entering ‘turnaround’ phase, new CEO saysNovember 9, 2024 | bizjournals.comEmergent BioSolutions rises 23.7%November 9, 2024 | markets.businessinsider.comEmergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 9, 2024 | finance.yahoo.comEmergent BioSolutions (NYSE:EBS) Stock Price Up 7.9% on Analyst UpgradeEmergent BioSolutions (NYSE:EBS) Shares Up 7.9% Following Analyst UpgradeNovember 8, 2024 | marketbeat.comEmergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa MagicNovember 8, 2024 | seekingalpha.comEmergent BioSolutions Shows Strong Q3 2024 RecoveryNovember 8, 2024 | markets.businessinsider.comEmergent BioSolutions rises 36.1%November 8, 2024 | markets.businessinsider.comEmergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment StrongNovember 8, 2024 | msn.comMpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024November 7, 2024 | benzinga.com Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Media Mentions By Week EBS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EBS News Sentiment▼0.440.46▲Average Medical News Sentiment EBS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EBS Articles This Week▼105▲EBS Articles Average Week Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LGND News GERN News MNKD News DVAX News BCRX News CLDX News NVAX News MYGN News INVA News OPK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:EBS) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
